about
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsImmunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period.Growth modeling of the maternal cytokine milieu throughout normal pregnancy: macrophage-derived chemokine decreases as inflammation/counterregulation increases.Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma.Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy.CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment.Lymphocytic Choriomeningitis Virus Infection Demonstrates Higher Replicative Capacity and Decreased Antiviral Response in the First-Trimester PlacentaUpregulation of HLA-Class I and II in Placentas Diagnosed with Villitis of Unknown EtiologyBaby's First Macrophage: Temporal Regulation of Hofbauer Cell Phenotype Influences Ligand-Mediated Innate Immune Responses across GestationFrequency of Gestational Diabetes Mellitus Reappearance or Absence during the Second Pregnancy of Women Treated at Mayo Clinic between 2013 and 2018Regenerative Prophylaxis In UteroMaternal T Cells in the Human Placental Villi Support an Allograft Response during Noninfectious Villitis
P50
Q26784480-535972CA-5B03-4FD3-9ED5-4BA16ABA71DAQ34855293-E8B02B69-0608-4A4A-BEB3-EA447E74EEA0Q35050165-0B7E2174-2169-4796-A102-E2F1144040E1Q35239145-7CAF2BB3-042F-477B-8F7B-377C48837FACQ36060302-8DDB9E83-6FB1-4C0A-9679-A14981EE68AFQ39562562-5EDE8112-7824-4952-9144-12959C7ADA9CQ40054249-7413CC16-6D77-45EF-8029-E5EE902EFB8FQ47330272-1BBCDDBB-F48A-4B2C-A319-C50DC9E15018Q53283991-FA31564F-01CF-468F-B5A6-530CC74B7F94Q63246494-D767009D-204F-4EA2-AC20-0E9DCF9E0701Q89660468-3D7B2B6E-2523-430A-92F8-6A87583D32EEQ90660215-39E20708-7A5F-47F5-B9D9-9FAFECB52D6DQ92313960-3D4B8D2E-F45D-43B1-8087-D1E7FC813193Q92995784-BB2E9A8D-8A38-431F-B95F-8B6954FD9774Q93161643-321C013B-C8C0-457C-B074-6442D0EBEE0C
P50
description
investigador
@es
researcher
@en
name
Elizabeth Ann L Enninga
@en
type
label
Elizabeth Ann L Enninga
@en
prefLabel
Elizabeth Ann L Enninga
@en
P31
P496
0000-0003-3621-7335